Accelerating Biotech Trials through Preclinical Readiness
Ben Edwards, Chief Operating Officer at Avance Clinical, highlights the importance of addressing preclinical gaps to prevent trial delays.
- Early toxicology readiness is crucial for accelerating trial startup and regulatory approval.
- Strong scientific collaboration with CRO partners is necessary for creating a sound scientific argument for new drugs.
- Obtaining patient data early is vital for informed decision-making in the current funding climate.
Effective coordination across functions requires integrated teams and data visualization.
Edwards also notes a shift towards adaptive trial designs and the benefits of maintaining continuity with the same CRO.
Author's summary: Accelerate biotech trials with preclinical readiness.